128 related articles for article (PubMed ID: 37642368)
41. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
42. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
43. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
44. Neosetophomone B induces apoptosis in multiple myeloma cells via targeting of AKT/SKP2 signaling pathway.
Kuttikrishnan S; Ahmad F; Mateo JM; Prabhu KS; El-Elimat T; Oberlies NH; Pearce CJ; Akil ASA; Bhat AA; Alali FQ; Uddin S
Cell Biol Int; 2024 Feb; 48(2):190-200. PubMed ID: 37885161
[TBL] [Abstract][Full Text] [Related]
45. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
[TBL] [Abstract][Full Text] [Related]
46. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
47. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
[No Abstract] [Full Text] [Related]
48. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
49. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
[TBL] [Abstract][Full Text] [Related]
50. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
[TBL] [Abstract][Full Text] [Related]
51. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
52. Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p/BRD4 axis.
Liu D; Wang Y; Li H; Peng S; Tan H; Huang Z
Anticancer Drugs; 2022 Jan; 33(1):e145-e154. PubMed ID: 34387610
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
54. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
[TBL] [Abstract][Full Text] [Related]
55. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
56. BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway.
Xiao P; Chen X; Dong Z; Fan W; Chen Y; Su J; Wang Q; Ma L
Hematology; 2023 Dec; 28(1):2231739. PubMed ID: 37401850
[TBL] [Abstract][Full Text] [Related]
57. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Guo L; Wu Z
Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
[TBL] [Abstract][Full Text] [Related]
58. High expression of VARS promotes the growth of multiple myeloma cells by causing imbalance in valine metabolism.
Shi R; DU W; He Y; Hu J; Yu H; Zhou W; Guo J; Feng X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 48(6):795-808. PubMed ID: 37587064
[TBL] [Abstract][Full Text] [Related]
59. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
60. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
